Author

Isadora Martins de Sousa

Observed names: Isadora. M. Sousa, isadora sousa

Institution: AC Camargo Hospital

Observed institution: AC Camargo Hospital

OpenAlex ID: A5039166382

2025 · Matheus de Oliveira Andrade, Isabella Gonçalves Gutierres, et al. · The Breast · 25

PDF

Dose dense versus 3 weekly AC during neoadjuvant chemoimmunotherapy for triple negative breast cancer

2024 · Renata Colombo Bonadio, Isadora Martins de Sousa, et al. · npj Breast Cancer · 10

PDF

Pathologic complete response rates of patients with ER-low/HER2-negative breast cancer treated with neoadjuvant pembrolizumab plus chemotherapy in the neo-real study

2025 · Renata Colombo Bonadio, Monique Celeste Tavares, et al. · Breast Cancer Research and Treatment · 6

Prediction of pathologic complete response to chemoimmunotherapy in triple-negative breast cancer using tumor-infiltrating lymphocytes: Exploiting cutoff values.

2024 · ROMUALDO BARROSO-SOUSA, Isadora Martins de Sousa, et al. · Journal of Clinical Oncology · 3

PDF

Neoadjuvant pembrolizumab plus chemotherapy in older patients with early-stage triple-negative breast cancer: real-world insights from neo-real/GBECAM-0123

2026 · Mariana Carvalho Gouveia, Romualdo Barroso-Sousa, et al. · npj Breast Cancer · 2

PDF

Real life comparison between doxorubicin and cyclophosphamide (AC) dose-dense (dd) and conventional dose AC in patients with triple negative breast cancer (TNBC) under neoadjuvant treatment.

2024 · Flavia Cavalcanti Balint, Monique Celeste Tavares, et al. · Journal of Clinical Oncology · 1

Role of tumor-infiltrating lymphocytes in early-stage triple-negative breast cancer treated with KEYNOTE-522 in real-world setting

2026 · Renata Colombo Bonadio, Flávia Cavalcanti Balint, et al. · npj Breast Cancer

PDF

Differential response and survival across rare histologic subtypes of triple-negative breast cancer following neoadjuvant chemo-immunotherapy

2026 · Romualdo Barroso-Sousa, Mariana Carvalho Gouveia, et al. · npj Breast Cancer

PDF

Neoadjuvant pembrolizumab plus chemotherapy in germline BRCA-mutated early triple-negative breast cancer: a multicenter real-world cohort

2026 · Monique Celeste Tavares, Flávia C. Balint, et al. · npj Breast Cancer

Treatment patterns and safety of adjuvant therapy after chemoimmunotherapy for early-stage triple-negative breast cancer: real-world data from the Neo-Real/GBECAM 0123 study

2026 · Matheus de Oliveira Andrade, Renata Colombo Bonadio, et al. · Breast Cancer Research and Treatment

Outcomes of elderly patients with early-stage triple-negative breast cancer treated with the KEYNOTE-522 regimen.

2025 · Renata Colombo Bonadio, Flavia Balint, et al. · Journal of Clinical Oncology

Pathologic response in er-low early-stage breast cancer treated with neoadjuvant pembrolizumab plus chemotherapy

2025 · Renata Colombo Bonadio, Flávia Cavalcanti Balint, et al. · Brazilian Journal of Oncology

Evaluation of the impact on overall survival curves of patients with metastatic castration-sensitive prostate cancer staged with PET-PSMA and classified according to current prognostic criteria by volume and risk.

2025 · Isadora Martins de Sousa, Luciana de Moura Leite, et al. · Journal of Clinical Oncology

Abstract PO3-03-06: Real-world efficacy and safety of neoadjuvant pembrolizumab plus chemotherapy in Brazilian patients with early-stage triple-negative breast cancer

2024 · isadora sousa, Ana Carolina M. Comini, et al. · Cancer Research

Benefit of immune checkpoint inhibitors (ICI) for patients with advanced esophageal squamous cell carcinoma and low PD-L1 expression: A systematic review and meta-analysis.

2024 · Mario Machado Lopes, Viviane Alencar, et al. · Journal of Clinical Oncology

Clinical and pathological description of patients with triple negative breast cancer undergoing neoadjuvant chemotherapy and pembrolizumab in a Brazilian cancer center.

2023 · Isadora Martins de Sousa, Ana Carolina Carolina Marin Comini, et al. · Journal of Clinical Oncology

PDF

Immunotherapy versus tyrosine kinase inhibitors in advanced hepatocellular carcinoma in first-line setting: A systematic review and meta-analysis of randomized controlled trials.

2023 · Ana Carolina Carolina Marin Comini, Isadora Martins de Sousa, et al. · Journal of Clinical Oncology

PDF

Works count: 17

Citation count: 47

H-index: 3

I10-index: 2